Steven Cohen’s Insight Molecular Diagnostics IMDX Stock Holding History

Steven Cohen’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,250	Closed	-$40.2K	–	4429
2026 Q1	$40.2K	Buy	+12,250	New	+$71.1K	﹤0.01%	3671

Other funds holding IMDX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

FOR

Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Steven Cohen's IMDX Position: Q2 2026 in Review

Steven Cohen sold out of Insight Molecular Diagnostics (IMDX) in Q2 2026, closing a stake of 12,250 shares — an estimated $40.2K sold.

Steven Cohen first reported a position in IMDX in Q1 2026 and held it in 1 quarter. The position peaked at $40.2K in Q1 2026. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

Steven Cohen reported no remaining Insight Molecular Diagnostics position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 12,250 Insight Molecular Diagnostics shares in Q2 2026, an estimated $40.2K.
Steven Cohen first reported a position in Insight Molecular Diagnostics in Q1 2026 and held it in 1 quarter.
Steven Cohen's Insight Molecular Diagnostics position peaked at $40.2K in Q1 2026.
40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.